Phase I/IIa Trial Evaluating scAAV1.tMCK.NTF3 for Treatment of Charcot-Marie-Tooth Neuropathy Type 1A (CMT1A)
Status: Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 20 Jan 2020
Price : $35 *
At a glance
- Drugs ScAAV1 tMCK NTF3 (Primary)
- Indications Charcot-Marie-Tooth disease
- Focus Adverse reactions
- 20 Jan 2020 Last checked against the ClinicalTrials.gov record.
- 15 Oct 2019 Planned initiation date changed from 1 Jul 2019 to 1 Jan 2020.
- 15 Oct 2018 New trial record